Christopher Paul Denton

Christopher Paul Denton

Top Cited Scholar 2025
Auto-generated profile, based on publicly available information

Christopher Paul Denton

Centre for Rheumatology, Division of Medicine, University College London, London, UK

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in The Lancet
Verified
Journal Article
Closed access
CDChristopher P Denton
Christopher P Denton
DKDinesh Khanna
Dinesh Khanna

29 August 2024 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
GKGabor Kovacs
Gabor Kovacs
SBSonja Bartolome
Sonja Bartolome
CDChristopher P. Denton
Christopher P. Denton
MGMichael A. Gatzoulis
Michael A. Gatzoulis
SGSue Gu
Sue Gu
David MontaniDavid Montani
David Montani
Pulmonary hypertension (PH) is a haemodynamic condition characterised by elevation of mean pulmonary arterial pressure (mPAP) >20 mmHg, assessed by right heart catheterisation. Pulmonary arterial wedge pressure (PAWP) and pulmonary vascular resistance (PVR) distinguish pre-capillary PH (PAWP ≤15 mmHg, PVR >2 Wood Units (WU)), isolated post-capillary PH (PAWP >15 mmHg, PVR ≤2 WU) and combined post- and pre-capillary PH (PAWP >15 mmHg, PVR >2 WU). Exercise PH is a haemodynamic condition describing a normal mPAP at rest with an abnormal increase of mPAP during exercise, defined as a mPAP/cardiac output slope >3 mmHg/L/min between rest and exercise. The core structure of the clinical classification of PH has been retained, including the five major groups. However, some changes are presented herewith, such as the re-introduction of “long-term responders to calcium channel blockers” as a subgroup of idiopathic pulmonary arterial hypertension, the addition of subgroups in group 2 PH and the differentiation of group 3 PH subgroups based on pulmonary diseases instead of functional abnormalities. Mitomycin-C and carfilzomib have been added to the list of drugs with “definite association” with PAH. For diagnosis of PH, we propose a stepwise approach with the main aim of discerning those patients who need to be referred to a PH centre and who should undergo invasive haemodynamic assessment. In case of high probability of severe pulmonary vascular disease, especially if there are signs of right heart failure, a fast-track referral to a PH centre is recommended at any point during the clinical workup.

1 March 2020 in Autoimmunity Reviews
Verified
Journal Article
Open access
VSVanessa Smith
Vanessa Smith
AHAriane L. Herrick
Ariane L. Herrick
FIFrancesca Ingegnoli
Francesca Ingegnoli
NDNemanja Damjanov
Nemanja Damjanov
RARossella De Angelis
Rossella De Angelis
MCMaurizio Cutolo
Maurizio Cutolo
Capillaroscopy is a non-invasive and safe tool which allows the evaluation of the morphology of the microcirculation. Since its recent incorporation in the 2013 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for systemic sclerosis together with its assessed role to monitor disease progression, capillaroscopy became a 'mainstream' investigation for rheumatologists. Given its increasing use by a variety of physicians internationally both in daily practice to differentiate primary from secondary Raynaud's phenomenon, as well as in research context to predict disease progression and monitor treatment effects, standardisation in capillaroscopic image acquisition and analysis seems paramount. To step forward to this need, experts in the field of capillaroscopy/microcirculation provide in this very consensus paper their view on image acquisition and analysis, different capillaroscopic techniques, normal and abnormal capillaroscopic characteristics and their meaning, scoring systems and reliability of image acquisition and interpretation.

3 March 2014 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
SNSvetlana I. Nihtyanova
Svetlana I. Nihtyanova
BSBenjamin E. Schreiber
Benjamin E. Schreiber
VOVoon H. Ong
Voon H. Ong
DRDaniel Rosenberg
Daniel Rosenberg
PMPia Moinzadeh
Pia Moinzadeh
CDChristopher P. Denton
Christopher P. Denton
Objective: To assess survival and incidence of organ‐based complications in a large single‐center cohort of unselected systemic sclerosis (SSc) patients, and to explore predictors of survival and clinically significant pulmonary fibrosis (PF) and pulmonary hypertension (PH).Methods: The study cohort consisted of 398 consecutive SSc patients, followed up for up to 15 years. Cox proportional hazards analysis with demographic, clinical, and laboratory characteristics as predictor variables was used to develop prediction models for pulmonary complications and survival.Results: The overall survival estimate at the end of followup was 57% among patients with limited cutaneous SSc (lcSSc) and 50% among patients with diffuse cutaneous SSc (dcSSc) (P = 0.017). We found that greater age at disease onset, dcSSc, lower diffusing capacity for carbon monoxide (DLco), lower hemoglobin levels, higher serum creatinine levels, and the presence of PH or cardiac involvement were independent predictors of worse survival. Over the entire followup period, 42% of dcSSc patients and 22% of lcSSc patients developed clinically significant PF (P < 0.001). The variables that predicted clinically significant PF development were dcSSc, greater age at onset, lower forced vital capacity and DLco, and the presence of anti–topoisomerase I antibody, while the presence of anticentromere antibody was protective. There was no difference in cumulative incidence of PH between the 2 subsets—24% in lcSSc and 18% in dcSSc (P = 0.558). Incidence rates were 1–2% per year. The PH prediction model demonstrated that greater age at onset, increase in serum creatinine levels, lower DLco, and the presence of anti–RNA polymerase III or anti–U3 RNP antibodies were associated with increased risk of PH, while anti–topoisomerase I antibody positivity reduced the hazard.Conclusion: Our study provides data on long‐term outcome of SSc and the timing and frequency of major organ complications. The predictive models we present could be used as clinical tools for patient risk stratification and could facilitate cohort enrichment for event‐driven studies.

2 January 2007 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
CDChristopher P. Denton
Christopher P. Denton
PMPeter A. Merkel
Peter A. Merkel
DFDaniel E. Furst
Daniel E. Furst
DKDinesh Khanna
Dinesh Khanna
PEPaul Emery
Paul Emery
OCon Behalf Of The Cat‐192 Study Group The Scleroderma Clinical Trials Consortium
on Behalf Of The Cat‐192 Study Group The Scleroderma Clinical Trials Consortium
Objective: To evaluate CAT‐192, a recombinant human antibody that neutralizes transforming growth factor β1 (TGFβ1), in the treatment of early‐stage diffuse cutaneous systemic sclerosis (dcSSc).Methods: Patients with SSc duration of <18 months were randomly assigned to the placebo group or to 1 of 3 CAT‐192 treatment groups: 10 mg/kg, 5 mg/kg, 0.5 mg/kg. Infusions were given on day 0 and weeks 6, 12, and 18. The primary objective of this study was to evaluate the safety, tolerability, and pharmacokinetics of CAT‐192. Secondary outcomes included the modified Rodnan skin thickness score (MRSS), the Scleroderma Health Assessment Questionnaire, assessment of organ‐based disease, serum levels of soluble interleukin‐2 receptor, collagen propeptides (N propeptide of type I [PINP] and type III collagen), and tissue levels of messenger RNA for procollagens I and III and for TGFβ1 and TGFβ2.Results: Forty‐five patients were enrolled. There was significant morbidity and mortality, including 1 death in the group receiving 0.5 mg/kg of CAT‐192 and 3 deaths in the group receiving 5 mg/kg of CAT‐192. There were more adverse events and more serious adverse events in patients receiving CAT‐192 than in those receiving placebo, although these events were not more frequent in the high‐dose treatment group. The MRSS improved in all groups during the study, but there was no evidence of a treatment effect for CAT‐192. Improvement in the MRSS correlated with the disease duration (r = −0.54, P = 0.0008). Changes in the PINP level from baseline correlated with changes in the MRSS (r = 0.37, P = 0.027).Conclusion: We report the first evaluation of a systemically administered and repeatedly dosed anti‐TGFβ1 drug. In this pilot study, CAT‐192, in doses up to 10 mg/kg, showed no evidence of efficacy. The utility of clinical and biochemical outcome measures and the feasibility of multicenter trials of early dcSSc were confirmed.

20 February 2020 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
ODOliver Distler
Oliver Distler
SAShervin Assassi
Shervin Assassi
Vincent CottinVincent Cottin
Vincent Cottin
MCMaurizio Cutolo
Maurizio Cutolo
SDSonye K. Danoff
Sonye K. Danoff
TMToby M. Maher
Toby M. Maher
Systemic sclerosis (SSc) is a systemic autoimmune disease affecting multiple organ systems, including the lungs. Interstitial lung disease (ILD) is the leading cause of death in SSc.There are no valid biomarkers to predict the occurrence of SSc-ILD, although auto-antibodies against anti-topoisomerase I and several inflammatory markers are candidate biomarkers that need further evaluation. Chest auscultation, presence of shortness of breath and pulmonary function testing are important diagnostic tools, but lack sensitivity to detect early ILD. Baseline screening with high-resolution computed tomography (HRCT) is therefore necessary to confirm an SSc-ILD diagnosis. Once diagnosed with SSc-ILD, patients' clinical courses are variable and difficult to predict, although certain patient characteristics and biomarkers are associated with disease progression. It is important to monitor patients with SSc-ILD for signs of disease progression, although there is no consensus about which diagnostic tools to use or how often monitoring should occur. In this article, we review methods used to define and predict disease progression in SSc-ILD.There is no valid definition of SSc-ILD disease progression, but we suggest that either a decline in forced vital capacity (FVC) from baseline of ≥10%, or a decline in FVC of 5–9% in association with a decline in diffusing capacity of the lung for carbon monoxide of ≥15% represents progression. An increase in the radiographic extent of ILD on HRCT imaging would also signify progression. A time period of 1–2 years is generally used for this definition, but a decline over a longer time period may also reflect clinically relevant disease progression.